The Firm served as legal counsel to Swiss diagnostics company Proteomedix on a strategic collaboration with Labcorp to expand access to an innovative prostate cancer test.
Proteomedix announced on May 22 that it signed a licensing agreement with Labcorp, giving the life sciences company the exclusive U.S. rights to develop and commercialize its Proclarix prostate cancer test. The test measures the levels of several proteins, including prostate-specific antigen (PSA), to determine the risk of clinically significant prostate cancer for men.
Terms of the deal were not disclosed.
“There is an important unmet medical need for an accurate diagnosis of clinically significant prostate cancer by employing an innovative, simple blood test,” Proteomedix CEO Helge Lubenow said in the statement. “The future commercialization of this assay in the U.S. will significantly impact how care and treatment for men with elevated PSAs is managed. We are pleased to work with Labcorp to make this test available to improve care for more men in the U.S.”
Zurich-based Proteomedix, a company focused on transforming prostate cancer diagnosis, has identified novel biomarker signatures with utility in prostate cancer diagnosis, prognosis, and therapy management. The lead product Proclarix is a blood-based prostate cancer test panel and risk score currently available in Europe.